Research output per year
Research output per year
Caroline Day*, Clifford J. Bailey
Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review
Metformin is the only biguanide antihyperglycemic agent used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. It counters insulin resistance partly by increased insulin action (so-called insulin sensitizing effects) and partly via actions that are not directly insulin dependent. Metformin reduces hepatic glucose output by suppression of gluconeogenesis and glycogenolysis. In skeletal muscle, metformin increases insulin-mediated glucose uptake and glycogen storage. Other actions of metformin that contribute to its blood glucose-lowering effect are reduced fatty acid oxidation and increased glucose turnover, the latter occurring particularly in the splanchnic bed .... © 2007
Original language | English |
---|---|
Title of host publication | xPharm |
Subtitle of host publication | the comprehensive pharmacology reference |
Editors | S.J. Enna, David B. Bylund |
Publisher | Elsevier |
Number of pages | 4 |
ISBN (Print) | 978-0-08-055232-3 |
DOIs | |
Publication status | Published - 1 Dec 2011 |
Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review
Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review
Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review